Dr. Amer Karam Karam, MD

Dr. Karam practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Karam's NPI, 1851308860, was assigned on August 2, 2006. Dr. Karam graduated from American University of Beirut Faculty of Medicine in 2000. Dr. Karam holds California license A87777.

Dr. Karam's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Karam's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. Dr. Karam is also affiliated with Mills-Peninsula Medical Center. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Karam to 3 more hospitals and 1 medical group, each named with a free account. Dr. Karam's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Karam practices, 5 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Karam's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Karam is board certified in hospice and palliative medicine by the American Board of Internal Medicine. Dr. Karam is licensed in California.

Dmand AI lists hysterectomy and ovarian cyst among the conditions Dr. Karam treats.

CMS data shows 833 Medicare services from Dr. Karam across 10 procedure codes in 2024, for 352 Medicare patients. Medicare paid $101,600 for them.

CMS counts 352 Medicare patients who saw Dr. Karam in 2024. The largest group is 65 to 74, with 157 patients. 71% of them have high cholesterol, and 66% have high blood pressure. 26% are also on Medicaid. Their average risk score is 1.83, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Karam's median patient age at 59, with 99% women.

In 2024, Dr. Karam wrote 424 Medicare Part D claims for 95 patients. 81% of them were for generic drugs. CMS names the drug for 247 of them, across 9 drugs with 11 or more claims each, at $581,366 in total drug cost. In 2023, CMS named 144 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Karam for performance year 2024, reported as part of a group. Dr. Karam accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Karam as offering telehealth. CMS counts 41 procedures of removal of the uterus by Dr. Karam, more than 98% of the clinicians it reports for that procedure.

Dmand AI links 68 papers to Dr. Karam, published from 2008 to 2025. 2019 was the busiest year, with 5. The most frequent topics are Ovarian Neoplasms, Breast Neoplasms and Hysterectomy. Dr. Karam has published most often in Gynecol Oncol. Dr. Karam's most frequent co-authors are Oliver Dorigo, MD, PhD, Malte Renz, MD, PhD and Babak Litkouhi, MD.

CMS Open Payments shows 215 general payments to Dr. Karam from 13 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 73% of the total. Clovis Oncology, Inc. paid the most, $108,194.

Dmand AI lists 13 awards for Dr. Karam, most recently CMS Stage 1 EHR in 2013.

Dr. Karam graduated from American University of Beirut Faculty of Medicine in 2000.

Dr. Karam is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.